Stockreport

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF - Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval- PBGENE-HBV is the first in vivo gene editing program for chron [Read more]